Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
74,361,296
-
Number of holders
-
44
-
Total 13F shares, excl. options
-
23,673,230
-
Shares change
-
+3,279,406
-
Total reported value, excl. options
-
$63,207,000
-
Value change
-
+$8,569,595
-
Put/Call ratio
-
3.1%
-
Number of buys
-
15
-
Number of sells
-
-18
-
Price
-
$2.67
Significant Holders of Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) as of Q2 2021
53 filings reported holding CRVS - Corvus Pharmaceuticals, Inc. - Common Stock as of Q2 2021.
Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) has 44 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 23,673,230 shares
of 74,361,296 outstanding shares and own 31.84% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (8,053,298 shares), BVF INC/IL (3,678,626 shares), EcoR1 Capital, LLC (3,579,377 shares), ADAMS STREET PARTNERS LLC (3,275,616 shares), VANGUARD GROUP INC (1,109,218 shares), CHI Advisors LLC (719,132 shares), RENAISSANCE TECHNOLOGIES LLC (658,070 shares), DIMENSIONAL FUND ADVISORS LP (395,829 shares), TWO SIGMA INVESTMENTS, LP (309,653 shares), and TWO SIGMA ADVISERS, LP (288,300 shares).
This table shows the top 44 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.